Rationale for Locally Aggressive Treatment of Pancreatic Cancer
Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, John Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the improvement in systemic therapy for the treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
In 2 landmark studies, the combination of FOLFIRINOX [folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin] with gemcitabine and paclitaxel has shown significant improvement over the standard of care, gemcitabine alone.
